Celltech Results For 1994
Turnover for the financial year ended September 30, 1994, was flat at L14.2 million ($22.1 million) at the UK's Celltech group. Gross profits advanced slightly from L6.4 million a year ago to L6.7 million.
The company posted a greater loss of L8.7 million, compared with 36.8 million. The operating loss is broken down as follows: Celltech Biologics achieved operating profits of L2 million during the year and Celltech Therapeutics achieved a loss of L10.7 million. A year earlier, Celltech Biologics posted operating profits of L1.9 million and Celltech Therapeutics posted a loss of L6.8 million. The group loss per share was 11.0 pence.
Celltech invested L16.2 million in R&D and income from R&D milestone payments amounted to L5.5 million over the year, down slightly from the L6.1 million received in milestone payments last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze